GlassScriptPhysician profile
Gary G King
NPI 1285739813
$7,344.88
in general payments reported to CMS, 2019-2025
35 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $933 · 2021: $1,243 · 2022: $857 · 2023: $1,234 · 2024: $1,290 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.29 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,222.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,199.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $651.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $651.26 | 2021-2025 | |
| Glaxosmithkline, LLC. | $558.70 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $353.85 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $300.17 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.85 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $249.49 | 2019-2024 | Eliquis |
| Exact Sciences Corporation | $248.34 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $215.80 | 2019-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Amarin Pharma, INC. | $170.72 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $143.32 | 2024-2025 | Opsumit, Uptravi |
| Vanda Pharmaceuticals INC. | $124.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $118.74 | 2021-2023 | Airduo Digihaler |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $93.66 | 2019-2020 | |
| Corcept Therapeutics | $91.86 | 2024 | Korlym |
| Inspire Medical Systems, INC. | $82.94 | 2023-2025 | Inspire |
| Eisai INC. | $75.41 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.40 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $57.66 | 2022 | |
| Astellas Pharma US INC | $57.58 | 2019 | |
| Phathom Pharmaceuticals, INC. | $46.89 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $39.10 | 2020-2021 | |
| Allergan, INC. | $36.05 | 2020 | |
| Optinose US, INC. | $28.97 | 2025 | |
| Melinta Therapeutics, LLC | $28.55 | 2019 | |
| Esperion Therapeutics, INC. | $26.39 | 2020-2021 | |
| Corium, LLC | $23.92 | 2023 | Azstarys |
| Sumitomo Pharma America, INC. | $20.73 | 2024 | Gemtesa |
| Genentech USA, INC. | $18.96 | 2021 | |
| Daiichi Sankyo INC. | $16.53 | 2021 | |
| Lucid Diagnostics INC. | $16.20 | 2024 | |
| Axsome Therapeutics, INC. | $14.91 | 2023 | Auvelity |
| Amgen INC. | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.